ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) was downgraded by investment analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a report issued on Monday, MarketBeat Ratings reports.
Separately, Piper Sandler lowered ESSA Pharma from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $2.00 in a research note on Monday.
Get Our Latest Research Report on EPIX
ESSA Pharma Stock Up 4.3 %
ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.10. On average, sell-side analysts expect that ESSA Pharma will post -0.71 EPS for the current year.
Insider Transactions at ESSA Pharma
In related news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $1.53, for a total value of $12,055,761.99. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 7,883,053 shares of company stock worth $12,076,665. Company insiders own 14.70% of the company’s stock.
Institutional Trading of ESSA Pharma
A hedge fund recently bought a new stake in ESSA Pharma stock. EntryPoint Capital LLC bought a new stake in ESSA Pharma Inc. (NASDAQ:EPIX – Free Report) (TSE:EPI) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,420 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 75.12% of the company’s stock.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
- Five stocks we like better than ESSA Pharma
- What is a Stock Market Index and How Do You Use Them?
- Palantir Cracks $50, Is There Still Time to Get on Board?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Insider Buying Signals Upside for These 3 Stocks
- High Dividend REITs: Are They an Ideal Way to Diversify?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.